MSB

1.02%

99.0¢ mesoblast limited

Ann: End-Stage HF Results Selected For AHA Scientific Sessions, page-40

First 40 Last

Share
Profile

Follow
joeycav11

188 Posts.

133

03/10/18

13:04

Post #: 35976697
Share

Originally posted by AllanHU ↑

Doing some reading about the scientific sessions at the AHA conference. All info is taken from the selection criteria on the AHA website.

"Guidelines for Late-Breaking Science Presentations
Late-Breaking Science sessions are innovative and provide the latest breakthroughs in clinical science. These sessions provide notable exposure and recognition for studies likely to have a significant impact on clinical practice and/or to make significant advances in a scientific field."

- I don't see how negative results would be accepted under these criteria

"Simultaneous Journal Publication of Clinical Trials: Simultaneous publication of Clinical Trials is acceptable and encouraged as long as the embargo policies of the AHA and the involved journals are coordinated. If a clinical trial has been submitted to and accepted for publication, the presenter is responsible for insuring that the journal editor respects the AHA publication embargo policy. Publication of a clinical trial either in print or on a journal web site prior to presentation at Sessions will necessitate withdrawal of the trial from the program."

- I guess this means we won't hear any more results until after the conference.

The document also mentions that the abstract will be published in Circulation - For those unaware of the significance of this journal it is possibly the most respected cardiology journal going around. Overall the fact that this trial has been given 10min to present at such a major conference AND has had an abstract accepted for publication in circulation says that these results are at the very least thought provoking and possibly ground breaking.

That said, keep in mind that this is not a phase 3 trial and therefore is not grounds to PROVE success of the treatment. However it may indicate a likely positive phase 3 trial in the future.

EAll good news despite today wiping 15% off the SP. Good luck in the coming months everyone.

Expand

Hi Allan expectatations are this phase,2 trial will be enough for approvoal if they are good. We have Rmat designation for Lvad GL to U

MSB Price at posting: $2.09 Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

RCE

Recce's R327 found effective against E.coli during clinical trial

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

There are more pages in this discussion • 48 more messages in this thread...

First 40 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 99.0¢		Change 0.010(1.02%)		Mkt cap ! $1.130B

Open	High	Low	Value	Volume
99.5¢	$1.02	98.5¢	$5.507M	5.501M

Buyers (Bids)

No.	Vol.	Price($)
1	9996	99.0¢

Sellers (Offers)

Price($)	Vol.	No.
99.5¢	18069	3

View Market Depth

No.	Vol.	Price($)
1	9996	0.990
2	32880	0.985
4	71034	0.980
2	3059	0.975
7	145890	0.970

Price($)	Vol.	No.
0.995	1132	1
1.000	9500	3
1.005	35000	1
1.010	58113	4
1.015	46100	3

Last trade - 16.10pm 28/06/2024 (20 minute delay)

MSB (ASX) Chart

Ann: End-Stage HF Results Selected For AHA Scientific Sessions, page-40

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Recce's R327 found effective against E.coli during clinical trial

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: End-Stage HF Results Selected For AHA Scientific Sessions, page-40

Top Stories

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Recce's R327 found effective against E.coli during clinical trial

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News